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Objective—To determine if intravenous lidocaine is useful and safe as a treatment for equine ileus.
Study Design—Prospective double-blinded placebo-controlled trial.
Study Population—Horses (n¼ 32) with a diagnosis of postoperative ileus (POI) or enteritis and
that had refluxed 420L or had been refluxing for 424 hours.
Methods—Refluxing horses were administered lidocaine (1.3mg/kg intravenously [IV] as a bolus
followed by a 0.05mg/kg/min infusion) or saline (0.9% NaCl) solution placebo for 24 hours.
Variables evaluated included volume and duration of reﬂux, time to 1st fecal passage, signs of pain,
analgesic use, heart rate and arrhythmias, respiratory rate, temperature, days of hospitalization,
outcome (survival to discharge), and complications.
Results—Of the lidocaine-treated horses, 65% (11/17) stopped refluxing within 30 hours
(mean  SD, 15.2  2.4 hours) whereas 27% (4/15) of the saline-treated horses stopped within
30 hours. Fecal passage was significantly correlated with response to treatment; horses that re-
sponded to lidocaine passed feces within 16 hours of starting the infusion. Compared with placebo
treatment, lidocaine treatment resulted in shorter hospitalization time for survivors, equivalent
survival to discharge, no clinically significant changes in physical or laboratory variables, and no
difference in the rate of incisional infections, jugular thrombosis, laminitis, or diarrhea. Muscle
fasciculations occurred in 3 lidocaine-treated horses (18%).
Conclusion—IV lidocaine significantly improved the clinical course in refluxing horses with minimal
side effects.
Clinical Relevance—At the infusion rate studied, IV lidocaine is safe and should be considered for
the treatment of equine ileus.
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INTRODUCTION
POSTOPERATIVE ILEUS (POI) has remained animportant cause of increased morbidity and mortal-
ity in the early postsurgical period for horses, particularly
after small intestinal surgery.1 Similarly, clinical ileus is a
primary component of the syndrome of proximal duo-
denitis–jejunitis (PDJ). PDJ is associated with a relatively
This was a multicenter study with the reported cases submitted from the University of Minnesota, Utrecht University, University of
Tennessee, University of Missouri, and Michigan State University.
Presented in part at the Fifth Equine Colic Symposium, Athens, GA, September 25–28, 1994.
Address reprint requests to: Erin Malone, DVM PhD Diplomate ACVS, Department of Veterinary Population Medicine, 225K
VMC, 1365 Gortner Ave, St Paul, MN 55108. E-mail: malon001@tc.umm.edu
Submitted May 2005; Accepted August 2005
From the Department of Veterinary Population Medicine, University of Minnesota, Minneapolis, MN; the Department of Equine
Sciences, Utrecht University, Utrecht, the Netherlands; the Department of Large Animal Clinical Sciences, University of Tennessee,
Knoxville, TN; the Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO; Anoka Equine Veterinary
Services, Anoka, MN; and Randwick Equine Centre, Sydney, Australia.
r Copyright 2006 by The American College of Veterinary Surgeons
0161-3499/04
doi:10.1111/j.1532-950X.2005.00113.x
60
Veterinary Surgery
35:60–66, 2006
high complication rate, including gastric rupture, lam-
initis, renal dysfunction, and death.2 Various motility
modiﬁers have been used clinically and experimentally for
treatment of these syndromes, but none has gained wide-
spread favor in the horse, either because of lack of proven
efﬁcacy or potentially severe side effects.3,4
Intravenous (IV) lidocaine is a reemerging treatment
that has been successful in decreasing POI in humans.5,6
Lidocaine improved propulsive motility, provided pain
relief, and shortened hospital stays.5–7 Preliminary studies
have indicated IV lidocaine might also be a useful mo-
tility modiﬁer in the horse.1,8–10 We hypothesized that
lidocaine would decrease reﬂux duration, analgesic use,
and duration of hospital stay for horses with signs of
ileus. To test the safety and efﬁcacy of IV lidocaine for
treatment of equine POI and PDJ, we undertook a mul-
ticenter double-blinded prospective study.
MATERIALS AND METHODS
Criteria for Case Selection
Horses were included if they had a presumptive diagnosis
of PJD or POI concomitant with gastric reﬂux for  24
hours (42L/h) or had a cumulative reﬂux volume 420L in
o24 hours. Cases were admitted to the University of Min-
nesota, University of Tennessee, University of Missouri and
Michigan State University between April 1993 and April 1996
and to Utrecht University between September 2000 and April
2002. Cases were later excluded from analysis if the diagnosis
was altered by additional testing, surgery, or necropsy, or if
surgery was performed after initiation of the trial. Horses that
had nearly simultaneous discontinuation of reﬂux with the
onset of therapy were also eliminated from the study (n¼ 19
total exclusions).
Drug Administration Protocol
The study was performed in a randomized, double-blinded
format. Light-protected bottles, ﬁlled with 100mL of either
saline (0.9% NaCl) solution or 2% lidocaine (Phoenix Phar-
maceutical, Inc., St Joseph, MO) and labeled with only an
identiﬁcation number, were distributed to participating centers
in North America. At Utrecht University, distribution was
performed in a blinded manner by the pharmacist at that lo-
cation. For each horse, the selection of saline or lidocaine was
determined using a random number generator. After obtaining
owner permission, horses were treated with a slow IV lidocaine
bolus (1.3mg/kg) followed by an infusion (gravity ﬂow) at
0.05mg/kg/min for 24 hours or an equivalent volume of saline
placebo. Dosage was based upon preliminary studies to pro-
duce blood concentrations of 1–2mg/L without evidence of
toxicity. This range was selected based upon human analgesic
response and preliminary positive response in refluxing hors-
es.10,11 This dose rate has subsequently been demonstrated to
have jejunal effects and to remain below the toxic level in most
cases.8 No other motility agents could be used for 24 hours
before treatment or for 36 hours after initiation of lidocaine
infusion. Clinicians were asked to correct serum electrolyte
deﬁciencies before the start of the trial and electrolytes were
rechecked at the end of the infusion. Because of ethical con-
siderations, the code was broken at clinician request after the
24-hour posttreatment period to allow treatment with lido-
caine if the horse was initially treated to placebo and/or to
allow treatment with other agents in a timely manner.
Data Collection
Monitored variables included amount and duration of re-
ﬂux, time to 1st fecal passage, signs of pain as recorded in the
record (pawing, looking at ﬂank, rolling), analgesic use, heart
rate and arrhythmias, respiratory rate, temperature, days of
hospitalization, outcome (survival to discharge), and compli-
cations. Reﬂux (net volume of ﬂuid obtained) was measured
every 1–2 hours, depending upon reﬂux rates. In 14 cases (6
saline, 8 lidocaine), nasogastric tubes were maintained for
several hours at a time while in 18 cases (9 in each group),
tubes were passed intermittently on a scheduled basis. If nec-
essary to prevent spontaneous reﬂux losses, tubes were
plugged between reﬂux attempts. Physical examination vari-
ables and volume of reﬂux were recorded for 24 hours (or until
start of the trial) before drug infusion and continued until 24
hours after the infusion was discontinued. Data was also col-
lected on surgical lesions, other treatments, laboratory and
necropsy results. Cases were considered to respond to the
lidocaine if they stopped refluxing (o0.3L/h for  6 hours)
by 6 hours after discontinuation of the lidocaine infusion and
did not reﬂux again for at least 6 additional hours.
Data Analysis
Comparisons were made between lidocaine and placebo
cases for differences between groups using a Wilcoxon’ rank
sum test for response to treatment and w2 tests for categorical
data (anastomotic rates, complication rates). Complete blood
count results and serum electrolyte concentrations were com-
pared before and after lidocaine infusion using Student’s
paired t- tests. Comparisons between lidocaine and placebo
groups in terms of measured continuous variables were made
using Student’s t-test. Physical variables and reﬂux volumes
were compared before, during, and after lidocaine infusion
using a repeated measures ANOVA and a Bonferroni’s mul-
tiple comparison procedure when significant differences were
detected. Hourly reﬂux volumes were compared similarly,
both in terms of the average rate over each treatment period
and comparing the reﬂux rate for the last 6 hours of each
treatment period with the rate for the ﬁrst 6 hours of the next
treatment period. If a horse was admitted with significant re-
ﬂux (410L), the total volume was divided over a 6-hour pe-
riod to obtain an hourly rate.
A Kaplan–Meier method for estimation of survival func-
tion was used to check for differences in survival to discharge
and duration of hospitalization in survivors. Pearson’s corre-
lation coefﬁcients (r) were calculated to determine if there was
a relationship between 1st fecal passage and success rate or
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reﬂux duration. For the latter test, if cases did not stop
refluxing and/or refluxed for 44 days, the total duration of
reﬂux was recorded as 96 hours. In all statistical operations
Po.05 was considered significant and parametric tests
were used for numerical data after evaluation for normal
distribution.
RESULTS
Seventeen horses were treated with lidocaine (4 PDJ,
13 POI) and 15 horses were treated with saline placebo (4
PDJ, 11 POI). Five other horses were excluded because of
change in diagnosis or lack of continued nasogastric re-
ﬂux whereas another 14 horses were excluded for other
types of noncompliance with the study design (e.g., repeat
laparotomy performed, lidocaine administered unblind-
ed). The total dose of lidocaine was administered over a
mean ( SD) of 28.5 2.6 hours. Cases with a slow in-
fusion rate were still included in analyses.
Horses undergoing surgery were induced with keta-
mine ( guaifenesin) and maintained on isoﬂurane (ha-
lothane was used in 3 horses) in oxygen. Two horses were
not administered antibiotics (both treated for enteritis;
both in the lidocaine treatment group), 20 were admin-
istered procaine penicillin and gentamicin, 8 potassium
penicillin (7 gentamicin also), 1 ampicillin, and 1 ceftio-
fur. For horses with POI, lesions in the lidocaine-treated
group were ileal impaction (4), small intestinal entrap-
ment (3), small intestinal volvulus (2), small intestinal
foreign body (1), ascending colon displacement (2), and
ascending colon impaction (1). Side-to-side jejunocecos-
tomy was performed in 4 horses and jejunojejunal an-
astomosis (type not recorded) performed in 1 horse. In
the placebo-treated group, lesions were small intestinal
entrapment (2), small intestinal volvulus (1), other small
intestinal strangulating lesions (3), small intestinal mes-
enteric avulsion (1), chronic anastomotic stricture (1),
and ascending colon displacement or torsion (4). Side-to-
side jejunocecostomy was performed in 4 horses and re-
section with jejunojejunal anastomosis in 3 horses. The
number of anastomoses was not significantly different
between groups.
Of the lidocaine-treated horses, 11/17 (65%) stopped
within 30 hours of starting lidocaine treatment (lidocaine
responsive), including 8/13 with POI and 3/4 with PDJ.
This was significantly better than the placebo treated
horses, of which 4/15 (27%) stopped within the same time
frame (P¼ .04; 4/11 with POI, 0/4 with proximal enteri-
tis). In the lidocaine-treated group, nasogastric reﬂux
stopped an average of 15.2 2.4 hours after the start of
lidocaine infusion, with a median of 12.5 hours (Fig 1).
Reﬂux rates did not differ between groups at any of
the evaluated time points (hourly reﬂux/24 hour or hour-
ly reﬂux/6 hours). However, when groups were evaluated
for within-group differences, significant temporal de-
creases in reﬂux rate were noted only in the lidocaine
group. Mean hourly reﬂux rate was 2.4 0.3L/h in the
pretreatment period and this significantly decreased to
0.9 0.2L/h during lidocaine infusion and to
0.6 0.2L/h after infusion (Po.01; postinfusion values
not significantly different from the reﬂux rate during in-
fusion). Reﬂux rate in the placebo group did not signif-
icantly decrease either during or after saline infusion
(P¼ .11; pretreatment: 2.3  0.2L/h; during infusion:
1.5 0.3L/h; posttreatment 1.4 0.5L/h; Fig 2). Signif-
icant within-group decreases in reﬂux rate were also not-
ed when the last 6 hours of the pretreatment period was
compared with the ﬁrst 6 hours of lidocaine treatment
(3.0 0.7 versus 1.3  0.2L/h; Po.01); no difference was
noted between the reﬂux rate in the last 6 hours of lido-
caine treatment and the ﬁrst 6 hours posttreatment or in
either of the corresponding placebo pairs (P¼ .15).
Fecal passage was significantly correlated with reﬂux
response to lidocaine (P¼ .02; r¼ 0.43). Mean time to 1st
Fig 1. Graph of the percent of cases stopping reﬂux in each
time period after start of lidocaine or saline infusion.
Fig 2. Graph of hourly reﬂux rates (mean SEM) before,
during, and after treatment with either lidocaine or saline.
Significantly different from preinfusion rate for lidocaine-
treated group.
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fecal passage for lidocaine responsive cases was
15.8 4.1 hours (95% conﬁdence interval (CI) 7.0–16.0
hours) whereas mean time to 1st fecal passage for cases
deemed unresponsive to lidocaine (did not stop refluxing
within 30 hours of initiating treatment) was significantly
longer at 43.9 9.3 hours (95% CI 24.2–63.4 hours;
Po.01). There was no significant correlation between 1st
fecal passage and duration of reﬂux (P¼ .66).
Surviving lidocaine-treated horses spent significantly
fewer days in hospital compared with placebo-treated
horses (12.2 1.4 versus 17.4 2.1 days; P¼ .05). There
was no difference in hospital stay between POI and PDJ
survivors. There was no difference between the lidocaine
and placebo groups in survival to discharge. Ten of 17
(59%) horses in the lidocaine group were discharged
while 10/15 (67%) of the placebo group were discharged.
Seven of the placebo group also received lidocaine after
concluding placebo treatment; 4 were discharged. Of the
horses in the lidocaine group, 2 were euthanatized for
nongastrointestinal lesions (laminitis, renal failure), 1 be-
cause of colitis, 1 because of continued colic and adhe-
sions, and 3 because of continued reﬂux (no causative
agents found at necropsy). In the saline group, 2 were
euthanatized because of laminitis and 3 for continued
reﬂux (peritonitis and paralytic ileus in 1, no necropsy
performed in 2). No significant differences were noted
between groups in the rate of jugular thrombosis (0/15
placebo; 2/17 lidocaine), laminitis (3/15 saline, 2/17 lido-
caine), diarrhea (3/15 saline, 1/17 lidocaine), or incisional
infections (3/15 saline, 2/17 lidocaine). No horses devel-
oped detectable arrhythmias. Three lidocaine-treated
horses (18%) developed muscle fasciculations (1 during
bolus administration and 2 during infusion; blood con-
centration in one of the latter was 2.4mg/dL). One horse
had delayed detection of laminitis.
No differences in heart rate, respiratory rate, or
temperature were noted before, during or after treatment
either within or between groups. Pain notations and
medications decreased over time with no difference
between groups. No significant differences were noted
between groups in terms of complete blood count or
electrolyte concentrations. Few horses had complete
blood cell counts taken before, during and after treat-
ment. Of those with samples taken before and after
treatment, there were no differences in total nucleated
cell counts, neutrophil counts, bands, or ﬁbrinogen
levels in either group. Of those with samples taken
before and during treatment, the placebo group had
significantly fewer bands during treatment than before
treatment (0.33  0.28 versus 0.05 0.05 103/mL;
n¼ 4); no other significant differences were detected.
Anion gap values were above normal ranges in both
groups (lidocaine group: 12.7 0.9; placebo group:
15.7 2.1) and had returned to normal ranges (and were
not significantly different) after treatment. No changes in
calcium, chloride, sodium, or potassium concentrations
were noted after treatment in either group. Calcium con-
centrations were slightly below the normal range in the
placebo group (9.9 0.6mg/dL) but were not signiﬁ-
cantly different from the lidocaine group (10.7 0.4mg/
dL) or from posttreatment values (10.7 0.5mg/dL).
All other values were within normal ranges for our
laboratory.
DISCUSSION
Our results suggest that IV lidocaine is useful for the
treatment of gastric reﬂux in horses and is safe at the
infusion rate studied. IV lidocaine, administered after the
start of reﬂux, significantly decreased the amount of gas-
tric reﬂux and shortened hospital stay by a mean of
6  2.6 days compared with placebo-treated horses.
Lidocaine treatment completely eliminated gastric reﬂux
in 65% of the cases treated.
Lidocaine has been hypothesized to alter sympathetic
tone to the bowel by suppressing transmission through
afferent sensory pathways.5 Peritonitis, enteritis, serosal
damage, intestinal distension, endotoxemia, and surgical
manipulation have all been associated with increased
sympathetic stimulation experimentally.12–14 Lidocaine
may act to prevent the reﬂexive inhibition because of one
or more of these factors by blocking transmission
through afferent nerves.15 Many of these factors have
also been documented to increase the release of non-
adrenergic–noncholinergic neurotransmitters with a con-
comitant alteration in motility in rats and dogs.12,16,17
Lidocaine may be preventing the effects of these neuro-
hormonal agents rather than or in addition to altering
sympathetic neurotransmission. Potentially, lidocaine
may inhibit abnormal motility patterns in many cases
allowing the gut to ‘‘restart’’ in a more normal and co-
ordinated pattern of activity, similar to other anesthetic
agents.18 Alternately, lidocaine may prevent motility al-
terations primarily through its anti-inﬂammatory, anti-
endotoxic, or analgesic actions19–21 and may have direct
effects on ﬂuid accumulation.8 Lidocaine also had direct
effects on the proximal duodenum in vitro.22
In our study, lidocaine-treated horses had decreased
reﬂux rates and were more likely to stop refluxing within
30 hours of starting treatment than were placebo-treated
horses. Reﬂux rates do tend to slow naturally but our
results were consistent even when evaluated over a short-
er time frame (i.e., the 6-hour period on either side of the
24-hour blocks) and we could not detect a significant
temporal differences in reﬂux volumes in saline-treated
horses. We did not ﬁnd any significant differences be-
tween groups that would indicate more severe electrolyte
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abnormalities or more severe disease in placebo-treated
horses. Calcium concentration was below our normal
ranges in the placebo group but was normalized within 24
hours and did not correlate with improvement in reﬂux
status. Ionized calcium was not measured frequently
enough to be evaluated statistically and may still have
played a role in continuing reﬂux.2 Individual variability
in lidocaine serum concentrations has also been reported
to be high, likely inﬂuenced by cardiac output.8
Survival rates were not different between groups but
only 3/17 horses in the lidocaine-treated group were
euthanatized because of continued reﬂux, and complica-
tions were similar to previous reports of horses with these
lesions. No significant alterations in physical examination
variables were detected. Muscle fasciculations and ataxia
have been reported with IV lidocaine at this dose but
were rare in our study. Fasciculations were evident in 2
horses, 1 of which was receiving the initial bolus and the
other during infusion. The corresponding blood concen-
tration in the latter horse was higher than the target range
of 1–2mg/dL (2.4mg/dL). Both horses had low serum
protein concentrations (5–6mg/dL) at the time of infu-
sion. Lidocaine is extensively protein bound and in-
creased active drug may have been present in these
horses. However, 7 other lidocaine-treated horses had
similar protein concentrations without fasciculations.
Additionally, in a few cases, the drip rate was slower
than recommended. Side effects may have been observed
in these horses under a faster rate of infusion. After ap-
proximately 8 minutes, lidocaine is redistributed from the
plasma, meaning any side effects of the drug resolve
within minutes if the drug is discontinued.23 Correspond-
ing, fasciculations and ataxia in horses respond rapidly to
discontinuation or slowing of the infusion rate and no
horses required cessation of the infusion because of per-
sistent side effects. There is no evidence of structural
damage to nerve ﬁbers or cells after lidocaine toxicity in
other species15; however, because of the potential for in-
jury associated with ataxia in larger animals, careful
monitoring is required and the rate of administration
should be slowed or stopped with any signs of toxicity.
Horses do appear to be more sensitive to the effects of
lidocaine, with toxicity noted at much lower levels than in
most other species.21,24
Most horses that were lidocaine responsive stopped
refluxing during the infusion itself but response times
were distributed throughout that period. We recommend
a full 24-hour infusion and waiting 6 hours after infusion
to determine lidocaine responsiveness. However, we also
found a correlation between early fecal passage and re-
sponse to lidocaine infusion, similar to that observed by
Brianceau et al.8 It may be that fecal passage can be used
as an early indicator of response to treatment with horses
that do not pass fecal within 16 hours being unlikely to
respond to lidocaine. Whereas many factors can alter
defecation, the ascending colon is the last segment of in-
testine to regain normal activity during POI in humans.25
Potassium penicillin has also been shown to stimulate
colonic and cecal activity in the horse and to stimulate
defecation within 15 minutes of exposure or administra-
tion.26 Potassium penicillin was administered to 4 horses
in each of the groups; however, the significant correlation
between early fecal passage and response to lidocaine in-
fusion remained even when these cases were removed
from analysis.
Analgesic effects have been documented in humans
with lidocaine blood concentrations of 1.5mg/dL.11 No
significant changes in pain notations or analgesic
use were documented in our study. Lack of statistical
significance may be related to low numbers of colics ad-
ministered postoperative analgesics, low blood concentra-
tions of lidocaine in some horses, and/or insufﬁcient
sample size. Analgesic effects have been observed by the
some of the authors in laminitic horses (data not shown).
Delayed detection of laminitis could therefore be of con-
cern in lidocaine-treated horses. Close attention should
be paid to increased heat and digital pulses despite lack of
significant lameness. Similarly, although not observed in
this study, lidocaine infusion has the potential to mask
the pain associated with gastric expansion and regular
evaluation for reﬂux is recommended. Lidocaine infusion
does not have prolonged effects and the infusion can be
stopped to allow better evaluation if necessary; repeat
bolus is recommended each time the infusion is stopped
for more than 8 minutes.
Lidocaine can be locally irritating and can cause tem-
porary immune suppression. The latter effects are gener-
ally reversible and self-limiting. No consequences of the
anti-inﬂammatory actions of lidocaine were documented
in an emergency room study.19 However, chronic expo-
sure to lidocaine can result in impaired lymphocyte func-
tion in mice.27 We detected no changes in white blood cell
counts or body temperatures. The rate of jugular vein
thrombosis and incisional infections we observed were
less than or similar to other reports.28–30 Survival rates
and necropsy ﬁndings did not suggest fatal or other spe-
cific effects of the lidocaine. However, prolonged infu-
sions of lidocaine are probably not necessary and should
be avoided to minimize any risks associated with pro-
longed immunosuppression. Similarly, lidocaine cannot
be recommended for cases of known septic peritonitis at
least until the infection is under control.
Problems with the study included inconsistent rate of
drug administration (likely to underestimate treatment
efﬁcacy and side effects), prior belief that lidocaine is ef-
fective in the treatment of ileus (led to problems with
compliance to study guidelines and lack of inclusion of all
possible cases), and natural resolution of ileus that may
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have occurred in both groups. The placebo group un-
derwent 2 more jejunojejunal anastomotic procedures
than did the lidocaine group, potentially affecting the
success rates. Clinic-related differences in treatment of
refluxing horses may have similarly affected success rates.
Whereas we could detect minimal changes in the treat-
ment of these horses between centers, subtle differences
may play a more significant role than anticipated. Our
survival rates may also be skewed by the later treatment
of many placebo horses with lidocaine. Greater numbers
would assist in correcting these deﬁciencies but collecting
cases in a prospective manner was found to be very dif-
ﬁcult in North American veterinary clinics.
Summarily, lidocaine can act as a motility modiﬁer in
refluxing horses. We recommend a slow bolus of 1.3mg/
kg IV followed by a 24-hour infusion at 0.05mg/kg/min.
At this rate we found side effects to be minimal and in-
cluded muscle fasciculations, masking of pain, and po-
tentially ataxia. The dose should be monitored carefully
in horses with moderate-to-severe hypoproteinemia and/
or decreased cardiac output. Lidocaine blood concentra-
tions taken at 4–6 hours are recommended to allow for
individual variation. Further work should be done to
determine the prognostic value of fecal passage on horses
with ileus. Based upon the results of this study, horses
that do not stop refluxing within 17.6 hours and do not
defecate within 16 hours of starting treatment have a
poorer response rate and may require alternative therapy.
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